APA (7th ed.) Citation

Friedman, K. P., Gagne, M., Loo, L., Karamertzanis, P., Netzeva, T., Sobanski, T., . . . Rasenberg, M. (2020). Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization. Toxicological Sciences, 173(1), 202. https://doi.org/10.1093/toxsci/kfz201

Chicago Style (17th ed.) Citation

Friedman, Katie Paul, et al. "Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization." Toxicological Sciences 173, no. 1 (2020): 202. https://doi.org/10.1093/toxsci/kfz201.

MLA (9th ed.) Citation

Friedman, Katie Paul, et al. "Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization." Toxicological Sciences, vol. 173, no. 1, 2020, p. 202, https://doi.org/10.1093/toxsci/kfz201.